# Biobeat Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biobeat-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Boca Raton, US
- Website: www.bio-beat.com/
- Total disclosed funding: $50M
- Latest round: Series B (Dec 30, 2025)
- Investors on record: 4

## About

Biobeat Technologies Ltd., based in the US, develops innovative cuff-less blood pressure monitoring solutions that enhance the diagnosis and management of hypertension through advanced wearable technology.Biobeat Technologies Ltd. specializes in health technology, particularly in non-invasive blood pressure monitoring solutions. Founded in 2016 in Boca Raton, US. In December 2025, Biobeat Technologies Ltd. raised USD 50 million in series B funding co-led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical Technologies, LP, with participation from Kestra Medical Technologies, Inc.  The funding will support the commercialization of its blood pressure sensor. The company has completed a total of 1 deal, with the most recent completed on December 30, 2025.Biobeat Medical specializes in cuff-less blood pressure monitoring solutions, focusing on technologies that improve hypertension management. Their products consist of advanced wearable devices that provide continuous blood pressure monitoring, enabling healthcare professionals to generate detailed reports on cardiovascular health. The clientele includes healthcare providers, hospitals, and clinics, primarily across Europe and North America, where demand for accurate monitoring solutions is increasing.Biobeat Medical generates revenue through direct sales to healthcare professionals and institutions and offers subscription models for continuous access to their monitoring software. Their flagship cuff-less blood pressure monitoring systems are sold under a structured pricing model that includes both one-time purchases and recurring service fees. The company establishes agreements with healthcare providers to integrate its technology into patient care protocols, ensuring a steady revenue stream while enhancing patient outcomes. The company plans to utilize the December 2025 funding to target additional markets for geographic expansion, particularly in regions where the demand for non-invasive blood pressure monitoring is growing.

## Funding rounds

- Series B, Dec 30, 2025, $50M — OrbiMed Advisors, Ally Bridge Group, Kestra Medical Technologies, Inc., Elevage Medical Technologies, LP

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series B
- Kestra Medical Technologies, Inc. — Series B
- Elevage Medical Technologies, LP — Series B